We found that, compared to the normal bone marrow controls, expression of BCL6 is significantly higher (Figure 1A) and BACH2 is significantly lower (Figure 1B) in B-ALL patients. This evidence concerns the gene BCL6 and precursor B-cell acute lymphoblastic leukemia.